Physician profile
Michael Gerald Knapp
NPI 1689776148
$3,978.40
in general payments reported to CMS, 2019-2025
18 companies · $287 in 2025
The $287 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,334 · 2020: $952 · 2021: $515 · 2022: $39.09 · 2023: $129 · 2024: $724 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,138.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $960.02 | 2019-2025 | Breztri, Farxiga, Bevespi Aerosphere |
| Novo Nordisk INC | $781.35 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $368.68 | 2019-2021 | |
| Pfizer INC. | $327.38 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $315.61 | 2024 | Voquezna |
| Dexcom, INC. | $273.39 | 2023-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $157.80 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $137.21 | 2019-2024 | Eliquis |
| Lilly USA, LLC | $134.85 | 2019-2021 | |
| Amgen INC. | $124.11 | 2020 | |
| Janssen Pharmaceuticals, INC | $111.64 | 2019-2020 | |
| Eisai INC. | $82.58 | 2020-2021 | |
| Allergan, INC. | $56.39 | 2020 | |
| Sumitomo Pharma America, INC. | $45.13 | 2024-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $33.35 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $26.47 | 2025 | Flucelvax, Fluad |
| Mylan Specialty L.P. | $23.32 | 2022 | |
| Verona Pharma, INC. | $19.12 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Knapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.